NEW YORK (GenomeWeb) – RPRD Diagnostics announced today that it has signed an agreement to help Children's Minnesota develop a pharmacogenomic testing process.
Under the terms of the deal, Children's Minnesota will begin using RPRD's pharmacogenomic testing platform within its cancer and blood disorder clinic and its neurology/psychology practice. The partners will work together to implement the service. Additional terms were not disclosed.
"Comprehensive preemptive pharmacogenomic testing is the cornerstone of precision medicine, especially in pediatrics," Nancy Mendelsohn, senior medical director of specialty care at Children's Minnesota, said in a statement. "Collaborating with RPRD Diagnostics underscores our commitment to integrating pharmacogenomic medicine into the care of our patients with the goal of providing better care and better outcomes."
RPRD — short for Right Patient Right Drug — was spun out of the Medical College of Wisconsin last year to provide clinical pharmacogenomic testing services, beginning with an array-based test based on Thermo Fisher Scientific's PharmacoScan technology. The company said it aims to roll out more targeted genotyping panels, as well as its own next-generation sequencing-based PGx test, in the future.